Tag Archives: Ian Read

Pfizer’s mixed 1Q results spur M&A hopes; is Bristol-Myers a “done deal”?

The News: Pfizer Inc. said Tuesday (May 2, 2017) that first-quarter sales declined 2% year-over-year to $12.8 billion, missing analyst estimates of $13.1 billion, with the company highlighting one less… Read more »

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Pfizer misses 3Q views but gets nod for Prevnar from China; Mao would scowl, but not Xi

More than a year after pulling its vaccines out of one of the world’s most challenging but lucrative drug markets, Pfizer has moved back into China with a thumbs up for top-selling… Read more »

Pfizer Wins Bidding War for Medivation; But Why Bother?

Pharmaceutical giant Pfizer Inc. (New York City) is paying $14 billion to buy Medivation Inc. (San Francisco), a biotech company that sells a high-priced prostate cancer medication discovered by UCLA, according to the… Read more »